Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Cirrhosis

Free Subscription 25.08.2025 1 BMC Gastroenterol 1 Clin Res Hepatol Gastroenterol 1 Dig Dis 2 Dig Dis Sci 2 Gastroenterology 3 Hepatology 2 Intern Med 3 J Hepatol 2 Lancet

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Gastroenterol

1. HUANG WT, Cheng DL, Yin L, Dong L, et al
   A GLIM-defined malnutrition-based model for predicting prognosis of cirrhotic patients with portal hypertension following TIPS procedure.
   BMC Gastroenterol. 2025;25:586.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

2. SOPHASATH M, Tremblay M, Hogue C, Brisset A, et al
   Evaluation of a nutritional education guide designed for patients living with cirrhosis: A randomized controlled mixed-methods study.
   Clin Res Hepatol Gastroenterol. 2025;49:102672.
   PubMed         Abstract available
   
   

   
   Dig Dis

3. LI W, Tian Y, Jing L
   Diagnostic value and prognostic effect of miR-7-5p in cirrhosis.
   Dig Dis. 2025 Aug 13:1-17. doi: 10.1159/000547157.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

4. FAIZ M, Usman M, Irshad NUN
   Clinical Insights on "Applying Metabolomics and Aptamer-Based Proteomics to Determine Pathophysiologic Differences in Decompensated Cirrhosis Patients Hospitalized with Acute Kidney Injury".
   Dig Dis Sci. 2025 Aug 19. doi: 10.1007/s10620-025-09329.
   PubMed        
   
   
5. ABREU ES, Reginato PH, Pitanga JFJ, Borges PN, et al
   Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
   Dig Dis Sci. 2025 Apr 19. doi: 10.1007/s10620-025-09044.
   PubMed         Abstract available
   
   

   
   Gastroenterology

6. LOU TW, Ren TY, Fan JG
   An Unusual Cause of Hypolipidemia With Cirrhosis in a Father-Son Pair.
   Gastroenterology. 2025 Aug 21:S0016-5085(25)05901.
   PubMed        
   
   
7. ROHM TV, Dos Reis FCG, Cunha E Rocha K, Isaac R, et al
   Adipose Tissue Macrophages in Metabolic Dysfunction-Associated Steatohepatitis Secrete Extracellular Vesicles That Activate Liver Fibrosis in Obese Male Mice.
   Gastroenterology. 2025;169:691-704.
   PubMed         Abstract available
   
   

   
   Hepatology

8. SIDDIQUI MS, Muthiah M, Satapathy SK, Patidar K, et al
   Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
   Hepatology. 2023 Dec 13. doi: 10.1097/HEP.0000000000000720.
   PubMed         Abstract available
   
   
9. TAO J, Wu Z, Liang Y, Wang J, et al
   Lhx2 specifically expressed in hepatic stellate cells promotes liver regeneration and inhibits liver fibrosis.
   Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001201.
   PubMed         Abstract available
   
   
10. LI W, Chi Y, Xiao X, Li J, et al
    Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis.
    Hepatology. 2025;82:669-682.
    PubMed         Abstract available
    
    

    
    Intern Med

11. MAMIZU H, Matsushima K, Kumagai M, Kuwana C, et al
    Autopsy of a Patient with Hepatic Pleural Effusion Complicated by Pleurisy Associated with Sjogren's Syndrome.
    Intern Med. 2025;64:2489-2493.
    PubMed         Abstract available
    
    
12. OKUBO S, Takaki A, Sato I, Adachi T, et al
    Clinical Variables That Predict Liver-related Events in Steatotic Liver Disease Diagnosed by a Liver Biopsy.
    Intern Med. 2025;64:2425-2432.
    PubMed         Abstract available
    
    

    
    J Hepatol

13. ROMERO-CRISTOBAL M
    Cirrhosis recompensation: what it is and what it ought to be - insights from the philosophy of science.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02449-3. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
14. RIDOLA L, Riggio O
    Rifaximin and Survival in Cirrhosis: An Unmet Clinical Promise.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02446-8. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
15. NEUSCHWANDER-TETRI BA, Akbary K, Carpenter DH, Noureddin M, et al
    The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials.
    J Hepatol. 2025;83:790-799.
    PubMed         Abstract available
    
    

    
    Lancet

16. LOOMBA R, Morgan E, Yousefi K, Li D, et al
    Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2025;406:821-831.
    PubMed         Abstract available
    
    
17. NOUREDDIN M, Frias JP, Neff GW, Lucas KJ, et al
    Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet. 2025;406:719-730.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.